EMA’s Cancer ‘Pathfinder’ Project Targets Conditional Approvals, Endpoints & RWE

This second of a two-part article on the EU’s “Cancer Medicines Pathfinder” initiative looks at the trade-off between the benefits and risks of conditional drug approvals and differing perceptions of progression-free survival as a validated endpoint in cancer drug trials.